There are currently 554 clinical trials in Madison, Wisconsin looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Wisconsin, University of Wisconsin Hospital and Clinics, University of Wisconsin-Madison and University of Wisconsin Carbone Cancer Center - University Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer
NCT05216432
Recruiting
This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, catalytic subunit alpha (PIK3CA) mutation in blood and/or tumor per local assessment. The study will evaluate RLY-2608 as a single agent for patients with unresectable or metastatic solid tumors. It will als... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: UW Carbone Cancer Center, Madison, Wisconsin
Conditions: PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor, Endometrial Cancer
Register for Updates
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
NCT05126277
Recruiting
This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
01/24/2025
Locations: Uni Wisconsin School Med Pub Health, Madison, Wisconsin
Conditions: Lupus Nephritis
Register for Updates
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
NCT05655312
Recruiting
In this first-in human, phase I/IIa study, the safety and efficacy of \[212Pb\]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated as a monotherapy and in combination with Nivolumab in subjects with unresectable and metastatic melanoma.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
01/23/2025
Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Conditions: Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Mucosal Melanoma, Melanoma Stage III
Register for Updates
Brain Blood Flow Responses During Exercise
NCT05864950
Recruiting
Brain blood flow will be measured during exercise using magnetic resonance imaging.
Gender:
ALL
Ages:
Between 55 years and 69 years
Trial Updated:
01/22/2025
Locations: University of Wisconsin-Madison, Madison, Wisconsin
Conditions: Cerebrovascular Circulation, Magnetic Resonance Imaging
Register for Updates
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
NCT05068232
Recruiting
This this study is for individuals who have treatment-naïve extensive-stage small cell lung cancer (small cell lung cancer that wont respond to treatment). Doctors leading this study hope to learn if combining durvalumab, carboplatin and etoposide with hyofractionated ablative radiation therapy (radiation focused on certain parts of the body) will help treat your cancer and improve how long you can live with extensive-stage small cell cancer without it getting worse (progression-free survival).... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Conditions: Small-cell Lung Cancer, Extensive-stage Small-cell Lung Cancer, Lung Cancer
Register for Updates
Brain Blood Flow Responses During Exercise: Younger Cohort
NCT06446622
Recruiting
Brain blood flow will be measured during exercise using magnetic resonance imaging.
Gender:
ALL
Ages:
Between 20 years and 40 years
Trial Updated:
01/22/2025
Locations: University of Wisconsin-Madison, Madison, Wisconsin
Conditions: Cerebrovascular Circulation, Magnetic Resonance Imaging
Register for Updates
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
NCT03767348
Recruiting
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: University of Wisconsin-Carbone Cancer Center, Madison, Wisconsin
Conditions: Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC
Register for Updates
Pilot Effectiveness Trial of an ACT Self-help Workbook Tailored Specifically for Prisons
NCT06162624
Recruiting
The goal of this research study is to adapt an ACT-self-help workbook to the prison setting and determine the feasibility acceptability, and effectiveness of this workbook. Participants can expect to be in the study for 13 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Anxiety, Depression, Depression, Anxiety, Anxiety Disorders
Register for Updates
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
NCT05468489
Recruiting
This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC. Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows: * Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide) * Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/22/2025
Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Conditions: Extensive Stage Small Cell Lung Cancer
Register for Updates
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
NCT05257083
Recruiting
The purpose of this study is to compare the efficacy of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple myeloma patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2025
Locations: University of Wisconsin Hospital and Clinics, Madison, Wisconsin
Conditions: Multiple Myeloma
Register for Updates
Study Transplanting Bone Marrow Cells Into Salivary Glands to Treat Dry Mouth Caused by Radiation Therapy
NCT05820711
Recruiting
The goal of this clinical research study is to evaluate the safety and tolerability of injecting certain cells that you produce in your bone marrow called mesenchymal stem cells (MSCs) into your salivary glands. Participants will have head and neck cancer that was treated with radiation therapy, and in this study will: * Undergo a collection of bone marrow using a needle; * Donate saliva; * Undergo a salivary gland ultrasound; and, * Complete questionnaires that ask about dry mouth Participan... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
01/21/2025
Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Conditions: Head and Neck Cancer, Xerostomia
Register for Updates
Prospective Clinical Assessment Study in Children with Achondroplasia (ACH)
NCT04035811
Recruiting
This is a long-term, multi-center, observational study in children 2.5 to \<17 years with achondroplasia (ACH). The objective is to evaluate growth, ACH-related medical complications, assessments of health-related quality of life, body pain, functional abilities, cognitive functions, and treatments of study participants. No study medication will be administered.
Gender:
ALL
Ages:
Between 30 months and 17 years
Trial Updated:
01/21/2025
Locations: University of Wisconsin Madison - Waisman Center Bone Dysplasia Clinic, Madison, Wisconsin
Conditions: Achondroplasia
Register for Updates